METASTASIS
Clinical trials for METASTASIS explained in plain language.
Never miss a new study
Get alerted when new METASTASIS trials appear
Sign up with your email to follow new studies for METASTASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New radiation approach aims to safely treat Hard-to-Reach lung tumors
Disease control Recruiting nowThis early-stage study tests a personalized radiation technique called PULSAR for lung cancers located near the center of the chest. The goal is to make treatment safer while still effectively controlling the tumor. About 30 adults with primary or metastatic lung cancer will rece…
Matched conditions: METASTASIS
Phase: EARLY_PHASE1 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo takes on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new drug called ifinatamab deruxtecan (I-DXd), given alone or with other treatments, in men with metastatic castration-resistant prostate cancer (mCRPC) that has worsened despite hormone therapy. The trial aims to find safe doses and see if the drug can lower P…
Matched conditions: METASTASIS
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo targets tough breast cancer in early trial
Disease control Recruiting nowThis study tests two drugs, abemaciclib and bicalutamide, together in people with a type of metastatic breast cancer that has spread and is positive for androgen receptors but negative for HER2. The goal is to find the safest dose and see if the combination can control the diseas…
Matched conditions: METASTASIS
Phase: PHASE1, PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New pill-and-immunotherapy cocktail takes on advanced tumors
Disease control Recruiting nowThis study tests an experimental oral drug called Alintegimod (7HP349) combined with two standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, and liver cancers. The trial has two parts: first, finding a safe dose (p…
Matched conditions: METASTASIS
Phase: PHASE1, PHASE2 • Sponsor: 7 Hills Pharma, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug combo aims to boost chemo for tough bone cancer
Disease control Recruiting nowThis study tests whether adding four drugs (gefitinib, trametinib, disulfiram, and sunitinib) to standard chemotherapy helps people with osteosarcoma that has spread. About 45 participants with newly diagnosed or advanced disease will be enrolled. Researchers will check if the co…
Matched conditions: METASTASIS
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for Obesity-Linked endometrial cancer: experimental combo enters human trials
Disease control Recruiting nowThis early-stage trial tests the safety of combining two drugs, ONC201 and atezolizumab, in 58 women with advanced or recurrent endometrial cancer. The study includes both obese and non-obese participants to see if body weight affects treatment. The goal is to find the best dose …
Matched conditions: METASTASIS
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental 'Alarm' therapy aims to rev up immune system against Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new approach called Peptide Alarm Therapy (PAT) for people with advanced solid tumors that have not responded to at least one prior treatment, including immunotherapy. PAT is injected directly into a tumor along with a standard PD-1 inhibitor d…
Matched conditions: METASTASIS
Phase: PHASE1 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Glow-in-the-Dark dye could spare breast cancer patients unnecessary surgery
Diagnosis Recruiting nowThis study tests a special dye that makes cancer cells glow when applied to lymph nodes removed during breast cancer surgery. The goal is to help surgeons instantly tell if a sentinel lymph node contains cancer, so they only remove the nodes that are truly affected. The trial wil…
Matched conditions: METASTASIS
Sponsor: Yunnan Cancer Hospital • Aim: Diagnosis
Last updated Jun 26, 2026 13:26 UTC
-
Europe-Wide study to settle debate on surgery for spread gut tumors
Knowledge-focused Recruiting nowThis study looks at people with small intestinal neuroendocrine tumors that have spread and cannot be cured. It compares those who had surgery to remove the main tumor plus other treatments against those who had only other treatments. The goal is to see if surgery helps patients …
Matched conditions: METASTASIS
Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
New study aims to find best treatments for limited cervical cancer spread
Knowledge-focused Recruiting nowThis study looks back at medical records of 350 people with cervical cancer that has come back or spread to a few spots. The goal is to see how well treatments like radiation or surgery work, alone or with chemotherapy. Researchers want to find out which patients benefit most fro…
Matched conditions: METASTASIS
Sponsor: Tata Memorial Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Scientists Fine-Tune radioactive drug dosing for prostate cancer
Knowledge-focused Recruiting nowThis study looks at how much radiation reaches tumors and healthy organs during a treatment called 177Lu-PSMA-617 for advanced prostate cancer that has spread. Researchers want to see if the radiation dose can predict how well the treatment works and what side effects might occur…
Matched conditions: METASTASIS
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC